Nkarta to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month:

Stifel 2025 Healthcare Conference
November 12, 2025
10:40 a.m. ET – fireside chat

TD Cowen’s Immunology & Inflammation Summit
November 13, 2025
5 p.m. ET – fireside chat

A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com. 

Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
[email protected]

You May Also Be Interested In

• CORRECTION -- Carahsoft Strengthens Public Sector Cybersecurity Through Key Cybersecurity and Zero Trust Government Events in 2026
• Terra Innovatum Global Reports Second Quarter 2026 Financial Results and Announces Webinar to Discuss Operational Progress
• IBNAi Expands Digital Asset Ecosystem with Branded Enterprise-Grade Wallets Through Fireblocks